RxDoctor Payments DataLook up a doctor →

Gloria Stevens, MD

Procedural Dermatology · Upland, CANPI 1699836288

Payments from drug & device makers

$23,193in general payments, 2019–2025

Across 619 payments — averaging $37.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Galderma Laboratories, L.p.$2K
  • Pfizer$2K
  • Sanofi$1K
  • LEO Pharma Inc.$1K
  • Amgen$1K
  • plus $13K from 39 others

What the payments were for

  • Speaking & faculty fees$4672%
  • Food & beverage$22,53597%
  • Education$1911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,193 in reported general payments places this provider in the 80th percentile of 108 procedural dermatology providers in California.

See all procedural dermatology providers in California

Medicare billing

Part B allowed, 2024
$319,348
Medicare patients
691
Services billed
4,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast14$68,243
OpzeluraRuxolitinib Phosphate13$33,384
Metronidazole102$4,412
Ketoconazole223$3,029
Fluorouracil42$2,928
Calcipotriene16$2,100
Clobetasol Propionate51$1,820
Azelaic Acid23$1,799
Fluocinonide56$1,786
Alclometasone Dipropionate50$1,388
Doxycycline Hyclate62$1,137
Mupirocin155$1,052
ValacyclovirValacyclovir Hcl51$967
Desonide30$950
Fluocinonide-EFluocinonide/Emollient Base16$786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,207$68,24314 claims
Incyte CorporationOpzelura$652$33,38413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 108 procedural dermatology providers in California.

Other procedural dermatology in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →